Volume 25, Issue 9, Pages (September 2017)

Slides:



Advertisements
Similar presentations
Molecular Therapy - Nucleic Acids
Advertisements

Molecular Therapy - Nucleic Acids
Targeted Disruption of V600E-Mutant BRAF Gene by CRISPR-Cpf1
Volume 8, Issue 3, Pages (March 2017)
Dan Ding, Kaiyuan Chen, Yuedan Chen, Hong Li, Kabin Xie 
Mutation Spectrum of the Survival of Motor Neuron 1 and Functional Analysis of Variants in Chinese Spinal Muscular Atrophy  Yu-jin Qu, Jin-li Bai, Yan-yan.
Molecular Therapy - Nucleic Acids
Correction of a Genetic Disease in Mouse via Use of CRISPR-Cas9
Volume 25, Issue 6, Pages (June 2017)
Volume 25, Issue 9, Pages (September 2017)
Mouse Genome Engineering via CRISPR-Cas9 for Study of Immune Function
Volume 154, Issue 6, Pages (September 2013)
Molecular Therapy - Nucleic Acids
Volume 13, Issue 2, Pages (October 2015)
Double Heterozygosity for a RET Substitution Interfering with Splicing and an EDNRB Missense Mutation in Hirschsprung Disease  Alberto Auricchio, Paola.
Genome Engineering with CRISPR-Cas9 in the Mosquito Aedes aegypti
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Volume 7, Issue 3, Pages (September 2016)
Molecular Therapy - Nucleic Acids
Volume 13, Issue 6, Pages (December 2013)
Identification and differential expression of human collagenase-3 mRNA species derived from internal deletion, alternative splicing, and different polyadenylation.
USH2A Gene Editing Using the CRISPR System
Supplemental Figure 3 A B C T-DNA 1 2 RGLG1 2329bp 3 T-DNA 1 2 RGLG2
Volume 22, Issue 2, Pages (February 2014)
Structure of the GM2A Gene: Identification of an Exon 2 Nonsense Mutation and a Naturally Occurring Transcript with an In-Frame Deletion of Exon 2  Biao.
Molecular Therapy - Nucleic Acids
Volume 18, Issue 2, Pages (April 2005)
A Rare Case of Hypohidrotic Ectodermal Dysplasia Caused by Compound Heterozygous Mutations in the EDAR Gene  Yutaka Shimomura, Nobuyuki Sato, Akinori.
Volume 8, Issue 3, Pages (March 2017)
Propionic and Methylmalonic Acidemia: Antisense Therapeutics for Intronic Variations Causing Aberrantly Spliced Messenger RNA  A. Rincón, C. Aguado, L.R.
Volume 154, Issue 6, Pages (September 2013)
Simultaneous Reprogramming and Gene Correction of Patient Fibroblasts
Current Progress in Therapeutic Gene Editing for Monogenic Diseases
A Homozygous Nonsense Mutation in Type XVII Collagen Gene (COL17A1) Uncovers an Alternatively Spliced mRNA Accounting for an Unusually Mild Form of Non-Herlitz.
Volume 14, Issue 6, Pages (February 2016)
A Presenilin-1 Truncating Mutation Is Present in Two Cases with Autopsy-Confirmed Early-Onset Alzheimer Disease  Carolyn Tysoe, Joanne Whittaker, John.
VSV-G-Enveloped Vesicles for Traceless Delivery of CRISPR-Cas9
Targeted Myostatin Gene Editing in Multiple Mammalian Species Directed by a Single Pair of TALE Nucleases  Li Xu, Piming Zhao, Andrew Mariano, Renzhi.
Volume 10, Issue 2, Pages (February 2018)
Volume 25, Issue 11, Pages (November 2017)
Volume 2, Issue 1, Pages (January 2014)
Volume 25, Issue 11, Pages (November 2017)
Volume 25, Issue 1, Pages (January 2017)
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Inclusion of jaagsiekte sheep retrovirus proviral elements markedly increases lentivirus vector pseudotyping efficiency  Patrick L. Sinn, Erin R. Burnight,
Alternative Splicing in the α-Galactosidase A Gene: Increased Exon Inclusion Results in the Fabry Cardiac Phenotype  Satoshi Ishii, Shoichiro Nakao, Reiko.
Volume 25, Issue 2, Pages (February 2017)
Molecular Therapy - Nucleic Acids
Correct mRNA Processing at a Mutant TT Splice Donor in FANCC Ameliorates the Clinical Phenotype in Patients and Is Enhanced by Delivery of Suppressor.
Volume 23, Issue 3, Pages (March 2015)
Assessing the Functional Characteristics of Synonymous and Nonsynonymous Mutation Candidates by Use of Large DNA Constructs  A.M. Eeds, D. Mortlock, R.
Annemieke Aartsma-Rus, Anneke A. M. Janson, Wendy E
CRISPR/Cas9-Mediated Deletion of CTG Expansions Recovers Normal Phenotype in Myogenic Cells Derived from Myotonic Dystrophy 1 Patients  Claudia Provenzano,
Volume 17, Issue 2, Pages (August 2015)
Volume 26, Issue 6, Pages (June 2018)
Volume 16, Issue 2, Pages (February 2015)
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Volume 26, Issue 11, Pages (November 2018)
Mutation of the Ca2+ Channel β Subunit Gene Cchb4 Is Associated with Ataxia and Seizures in the Lethargic (lh) Mouse  Daniel L Burgess, Julie M Jones,
Molecular Therapy - Nucleic Acids
Exon Skipping in IVD RNA Processing in Isovaleric Acidemia Caused by Point Mutations in the Coding Region of the IVD Gene  Jerry Vockley, Peter K. Rogan,
Volume 18, Issue 4, Pages (May 2005)
Volume 10, Issue 2, Pages (February 2018)
Genome Editing Reveals Glioblastoma Addiction to MicroRNA-10b
Genome-Edited Triple-Recessive Mutation Alters Seed Dormancy in Wheat
Volume 27, Issue 13, Pages e4 (June 2019)
Presentation transcript:

Volume 25, Issue 9, Pages 1999-2013 (September 2017) Using CRISPR-Cas9 to Generate Gene-Corrected Autologous iPSCs for the Treatment of Inherited Retinal Degeneration  Erin R. Burnight, Manav Gupta, Luke A. Wiley, Kristin R. Anfinson, Audrey Tran, Robinson Triboulet, Jeremy M. Hoffmann, Darcey L. Klaahsen, Jeaneen L. Andorf, Chunhua Jiao, Elliott H. Sohn, Malavika K. Adur, Jason W. Ross, Robert F. Mullins, George Q. Daley, Thorsten M. Schlaeger, Edwin M. Stone, Budd A. Tucker  Molecular Therapy  Volume 25, Issue 9, Pages 1999-2013 (September 2017) DOI: 10.1016/j.ymthe.2017.05.015 Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions

Figure 1 CRISPR-Based Correction of an Alu Insertion in MAK (A) Schematic representation of our CRISPR-Cas9/HDR strategy for the correction of the Alu insertion (top; red box) in MAK. sgRNAs tested are indicated by arrows. A donor plasmid (middle; HDR cassette) containing 500 bp of homology flanking a floxed puromycin selection cassette and the wild-type exon 9 sequence was co-transfected using various ratios of sg1-SpCas9-expressing plasmid, resulting in the repaired allele (bottom). (B) Representative gel image of T7E1 assays in HEK293T cells for each MAK sgRNA developed; a previously reported sgRNA targeting the EMX1 locus was included as a control.24 (C) Representative gel image demonstrating restoration of wild-type MAK transcript in sg1-SpCas9-treated, puromycin-selected, iPSC-derived photoreceptor precursor cells from a patient with molecularly confirmed MAK-associated retinitis pigmentosa. (D) Representative gel image confirming HDR in selected iPSC clones. +/+ indicates unaffected control cells; A/A indicates uncorrected patient iPSCs. (E) Representative gel image demonstrating restoration of wild-type MAK transcript in one puromycin-selected iPSC clone (clone 6) from a patient with molecularly confirmed MAK-associated retinitis pigmentosa. (F) Representative gel image confirming restoration of MAK protein expression in corrected iPSC clone 6. Molecular Therapy 2017 25, 1999-2013DOI: (10.1016/j.ymthe.2017.05.015) Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions

Figure 2 CRISPR-Cas9 Correction of the Deep Intronic IVS26 Mutation in CEP290 (A) Location of the two single guide RNAs. (B) sgRNA1 and 2 were designed to generate S. pyogenes Cas9-induced deletions that remove the mutant nucleotide and normalize CEP290 pre-mRNA splicing in hiPSCs homozygous for the CEP290 c.2991+1655A > G mutation (nucleotide 1655 of intron 26 is underlined). The gray box represents the 3′ end of the cryptic exon X. (C) Quantification of indel formation frequency and loss of the CEP290 disease-causing mutation with the single- or dual-guide strategy. (D–F) Representative sequence alignments (D) and phase-contrast images (4×) of two CEP290 clones: clone #3 (E), unchanged, and clone #12 (F), homozygous deletion. (G) CEP290 transcript analysis by semiquantitative RT-PCR. (Top) Amplicons obtained using primers located in exons 26 and 27 (E26, E27; EX represents inclusion of the cryptic exon X). (Bottom) Amplicons obtained with primers located in exons 26 and X. GAPDH was amplified as a control. (H) Western blot demonstrating the increase in full-length CEP290 protein expression in LCA-iPSCs with no (clone #3), one (clone #88), or two (clone #12) repaired alleles. Nitrocellulose Ponceau S. staining is shown to demonstrate even sample processing and loading. Molecular Therapy 2017 25, 1999-2013DOI: (10.1016/j.ymthe.2017.05.015) Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions

Figure 3 CRISPR-Cas9 Correction of the Deep Intronic IVS26 Mutation in CEP290 Using S. aureus Cas9 (A) Schematic representation of our paired guide strategy for the correction of the deep intronic IVS26 cryptic splice site mutation in CEP290. Two guides targeting upstream (sg3 and sg4) of the IVS26 mutation (red box) were each paired with two guides (sg5 and sg6) targeting downstream of the mutation to delete the exon X sequence and IVS26 mutation. (B) Representative gel image showing sg4/5-SaCas9-mediated IVS26 deletion in patient-derived iPSCs. Two lines of patient-derived iPSCs carrying homozygous IVS26 genotypes and those from a control unaffected individual were transfected with sg4/5-SaCas9-expressing plasmid (+) or Cas9 only (−). (C) Representative gel image demonstrating restoration of CEP290 transcript in sg4/5-SaCas9-treated iPSCs. POLR2A was amplified as a loading control. RET, human control retina cDNA. (D) Schematic representation of our CRISPR-Cas9/HDR strategy for the correction of the IVS26 cryptic splice site mutation (top; red box) in CEP290. Sg4/5RNA pair-expressing plasmid was co-delivered with a donor plasmid (middle; HDR cassette) containing 500 bp of homology flanking a floxed puromycin selection cassette and the wild-type IVS26 sequence resulting in the repaired allele (bottom). (E) Bright field image of a homozygous IVS26 patient-derived iPSC clone post-puromycin selection (note normal feeder-free iPSC morphology). Scale bar, 400 μM. (F) Representative gel image of genomic DNA from iPSC clones co-transfected with sg4/5-expressing plasmid and donor plasmid and cultured under puromycin selection. (G) Representative gel image demonstrating restoration of CEP290 transcript in sg4/5-SaCas9/donor-plasmid-treated iPSC clones. POLR2A was amplified as a loading control. WT, unaffected control iPSC cDNA; IVS, uncorrected patient-derived iPSCs carrying homozygous IVS26 alleles. (H) Western blot demonstrating restoration of full-length CEP290 protein in CRISPR/HDR-treated iPSC clones. Anti-α-Tub was used as a loading control. Molecular Therapy 2017 25, 1999-2013DOI: (10.1016/j.ymthe.2017.05.015) Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions

Figure 4 Allele-Specific Targeting of the Dominant Gain-of-Function Pro23His Mutation in RHO (A) Nucleotide and amino acid sequences of unaffected (P23) and affected (H23) RHO alleles. Underlined sequences indicate guides targeting each allele. Red text indicates mutation (c.68 C > A transversion at codon 23) lying in the seed region of each guide. (B) Representative gel image of T7E1 assays in HEK293T cells for each RHO sgRNA tested. (C) Histogram showing percent NHEJ in HEK293T cells transfected with each guide. Efficiency was quantified by subcloning and Sanger sequencing (please refer to Materials and Methods for further details). At lest 61 clones were sequenced per transfection. Data are represented as mean ± SEM. n = 3; *p < 0.01; **p < 0.001. (D) Representative gel image of T7E1 assays in patient-derived iPSCs (+/P23H) and iPSCs from an unaffected individual (+/+) transfected with plasmids expressing the sgH23-2 guide and SaCas9. (E) Schematic representation of our CRISPR-Cas9/HDR strategy for the correction of the Pro23His mutation (top; red box) in RHO. Sg3-hSpCas9-expressing plasmid was co-delivered with a donor plasmid (middle; HDR cassette) containing 500 bp of homology flanking a floxed puromycin selection cassette and the wild-type (Pro) sequence, resulting in the repaired allele (bottom). (F) Representative gel image of genomic DNA from iPSC clones co-transfected with sg3-expressing plasmid and donor plasmid and cultured under puromycin selection. (G) Schematic of transgene cassette plasmid carrying the allele-specific guide H23-2 and the humanized SaCas9 expression cassettes flanked by AAV2 ITRs packaged into the AAV5 serotype vector. (H) Representative gel image of T7E1 assays performed on genomic DNA isolated from the retinas of two animals treated unilaterally with AAV2/5-sgH23-2-SaCas9 vector. Amplicons were gel purified, subcloned, and sequenced via Sanger sequencing. Sequences from recovered clones (I) were aligned using Lasergene DNA analysis software. The percentage of alleles demonstrating NHEJ is indicated at the bottom of each lane. The rs7984 A/G SNP occurs 93 bp upstream of the Pro23His mutation. The P23 allele carries the rs7984 A nucleotide (top; underlined and italicized), whereas the H23 allele carries the rs7984 G nucleotide (second from top; underlined and italicized). Sequenced amplicon clones from sgH23-2-treated animals revealed formation of indel in the H23 allele only. Molecular Therapy 2017 25, 1999-2013DOI: (10.1016/j.ymthe.2017.05.015) Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions